drugset / Trial / NCT04305392
Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Study to evaluate pharmacokinetics, pharmacodynamics and safety of SHR4640 in patients with mild, moderate hepatic impairment and normal liver function in phase I clinical study.
Timeline
- Start
- 2020-08-04
- Primary completion
- 2022-12
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR4640 | Small molecule | — | Oral |
Indications
No indication recorded.